Results 21 to 30 of about 19,810 (255)

Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate [PDF]

, 2016
BACKGROUND: Targeted alpha therapy has been postulated to have great potential for the treatment of small clusters of tumour cells as well as small metastases.
Baüm, R.P. (Richard), Blois, E. (Erik) de, Breeman, W.A.P. (Wouter), Bruchertseifer, F. (Frank), Chan, H.S. (Ho Sze), Jong, M. (Marion) de, Koelewijn, S. (Stuart), Konijnenberg, M. (Mark), Morgenstern, A. (Alfred)   +8 more
core   +15 more sources

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT

Current Oncology, 2021
Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs).
Erica S. Tsang, Gayle Funk, Janet Leung, Grace Kalish, Hagen F. Kennecke   +4 more
doaj   +1 more source

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma [PDF]

Journal of Nuclear Medicine, 2020
Esthesioneuroblastoma is rare, with limited therapeutic options when unresectable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT). We report outcomes of PRRT in esthesioneuroblastoma from 2 referral centers.
Olfat Kamel, Hasan, Aravind S, Ravi Kumar, Grace, Kong, Kira, Oleinikov, Simona, Ben-Haim, Simona, Grozinsky-Glasberg, Rodney J, Hicks   +6 more
openaire   +2 more sources

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Cancer Medicine, 2021
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)   +13 more
doaj   +1 more source

Combination Therapies with PRRT

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
doaj   +1 more source

PEPTIDE RECEPTOR RADIONUCLIDE THERAPY

Unram Medical Journal, 2021
Peptide receptor radionuclide therapy (PRRT) is an effective and usually well-tolerated treatment for unresectable or metastatic neuroendocrine tumors expressing somatostatin receptors. Somatostatin analog which is labeled by ?- or ?-emitting radionuclide binds specifically to SSTRs abnormally expressed in NETs.
Rian Hidayatullah, Hendra Budiawan, Budi Darmawan, Erwin Affandi   +3 more
openaire   +1 more source

Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer

Pharmaceutics, 2021
In recent years, radionuclide therapy (RT) and targeted radionuclide therapy (TRT) have gained great interest in cancer treatment. This is due to promising results obtained in both preclinical and clinical studies.
Tyrillshall S. T. Damiana, Simone U. Dalm   +1 more
doaj   +1 more source

Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family [PDF]

, 2020
Head and neck paragangliomas are the most common clinical features of familial paraganglioma syndrome type 1 caused by succinate dehydrogenase complex subunit D (SDHD) mutation. The clinical management of this syndrome is still unclear.
Cantisani, Vito, Colao, Annamaria, Di Leo, Nicola, Faggiano, Antongiulio, Feola, Tiziana, Giannetta, Elisa, Isidori, Andrea M, Lenzi, Andrea, Modica, Roberta, Polti, Giorgia, Puliani, Giulia, Sesti, Franz, Verrico, Monica   +12 more
core   +1 more source

PEPTIDE BASED TARGETED RADIONUCLIDE THERAPIES; SCIENCE BEHIND THE SUCCESS.

Journal of Cancer and Allied Specialties, 2016
The radionuclide therapies for solid and liquid malignancies are emerging field nowadays. The targeted radionuclide therapies have been in use since 1945.
Mohammed H Al Rowaily, Daniele Dondi, Marco Chinol, Iqbal Munir, Muaadh AlAsbahi   +4 more
doaj   +1 more source

New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer

Frontiers in Chemistry, 2020
The high incidence of prostate cancer (PCa) increases the need for progress in its diagnosis, staging, and precise treatment. The overexpression of tumor-specific receptors for peptides in human cancer cells, such as gastrin-releasing peptide receptor ...
Xin Li, Huawei Cai, Xiaoai Wu, Li Li, Haoxing Wu, Rong Tian   +5 more
doaj   +1 more source